Pearl Steinzor

Real-world EHR study shows PREVENT equations deliver reliable CVD risk prediction despite missing data, guiding smarter outreach and recalibration.

A recent study identified persistent myocardial fibroblast activation in patients with heart failure with reduced ejection fraction, with distinct patterns by etiology.

John Barkett, MBA, discusses recent regulatory proposals to make massive health plan price files more usable.

Esketamine's monotherapy approval and new real-world data are forcing a reckoning for managed care.

A large cohort study across UK Biobank and All of Us finds RBM20 variants contribute to arrhythmogenic dilated cardiomyopathy.

Finerenone lowered cardiovascular death and HF events irrespective of coronary heart disease status but did not reduce atherothrombotic outcomes.

Vutrisiran not only slowed progression to advanced heart failure in patients with ATTR-CM but also reduced mortality and MACE among those who developed advanced disease.

Tirzepatide was associated with a significant reduction in a composite of major cardiovascular and kidney outcomes vs the GLP-1 agonist dulaglutide.

Steven Daveluy, MD, discusses 3-year findings that show 86% of patients remained HS flare-free throughout treatment, reinforcing the case for early intervention.

Medically tailored meals and produce show feasibility but no reduction in 90-day readmissions, according to one study.

The FDA has approved the first generic versions of dapagliflozin, expanding access to a widely used SGLT2 inhibitor.

Proactive adverse effect management helps patients with skin cancer stay on treatment longer, according to Todd Schlesinger, MD.

Key session speakers and abstract presenters share their highlights of attending AAD 2026.

Evaluation of more than 65,000 trials and 350,000 investigator sites highlights significant exposure in oncology and late-stage development.

New real-world data highlight sustained response and remission rates with esketamine nasal spray for patients with treatment-resistant depression.

Lauren Madigan, MD, shares open-label extension results demonstrating sustained improvements with avapritinib in patients with indolent systemic mastocytosis.

Melinda Gooderham, MD, MSc, FRCPC, discusses findings from the Latitude PsO 3001 and Latitude PsO 3002 studies evaluating zasocitinib.

Todd Schlesinger, MD, discusses how new immunotherapies and multidisciplinary care are reshaping treatment approaches for patients with advanced skin cancers.

Martina Porter, MD, discusses long-term results from the phase 3 STOP-HS program evaluating povorcitinib in patients with hidradenitis suppurativa.

April Armstrong, MD, MPH, discusses findings from the TRACE study, which evaluated the real-world effectiveness of tralokinumab in patients with skin of color with AD.

Linda Stein Gold, MD, shares efficacy and safety findings from the ICONIC-ADVANCE studies in moderate to severe psoriasis.

Clinicians need to adjust their diagnostic lens and counseling strategies in patients with skin of color, explained Joseph Lam, MD.

James Song, MD, discusses the direction teledermatology is heading and how more inclusive clinical trials can improve outcomes for patients of color.

Linda Stein Gold, MD, shares recent findings from the pooled phase 3 analysis of the ADORING 1 and ADORING 2 trials for atopic dermatitis.

John Barkett, MBA, discusses how health care price transparency can affect both patient out-of-pocket costs and overall health care spending.

Christopher Shade, PhD, shares insights for managed care leaders on oral peptide therapies.

Findings show sustained reductions in HbA1c, weight, blood pressure, inflammation, and lipids in patients with T2D and ASCVD or CKD.

Making health care prices public was supposed to cut costs. The reality is more complicated.

Active or severe atopic dermatitis throughout childhood and adolescence does not increase cardiometabolic risk, according to new research.

Conduction system pacing was found to be inferior to biventricular pacing for key outcomes in HFrEF with left bundle-branch block, despite lower costs.